تحميل
NASDAQHealthcareMedical - Devices
أحدث البيانات المتاحة
6.54 US$
+0.04 US$ · +0.62%
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
الإغلاق السابق
6.54 US$
+0.04 US$ · +0.62%
بعد ساعات التداول
6.54 US$
0.00 US$ · 0.00%
7 أكتوبر، 7:30 م ET
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
نطاق اليوم
السعر الحالي 6.54 US$
نطاق 52 أسبوعًا
السعر الحالي 6.54 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
نطاق اليوم
السعر الحالي 6.54 US$
نطاق 52 أسبوعًا
السعر الحالي 6.54 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 |
|---|---|---|---|
| الإيرادات | 13.55 مليون USD | 11.76 مليون USD | 9.75 مليون USD |
| تكلفة البضاعة المباعة | 6.38 مليون USD | 5.38 مليون USD | 4.26 مليون USD |
| الربح الإجمالي | 7.17 مليون USD | 6.38 مليون USD | 5.49 مليون USD |
| البحث والتطوير | 18.31 مليون USD | 15.12 مليون USD | 9.33 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 14.38 مليون USD | 11.17 مليون USD | 7.51 مليون USD |
| نفقات التشغيل | 32.69 مليون USD | 26.29 مليون USD | 16.84 مليون USD |
| دخل الفوائد | 269 ألف USD | 26 ألف USD | 49 ألف USD |
| الاستهلاك والإطفاء | 567 ألف USD | 521 ألف USD | 388 ألف USD |
| الدخل التشغيلي | −25.52 مليون USD | −19.92 مليون USD | −11.35 مليون USD |
| صافي الدخل | −25.32 مليون USD | −19.9 مليون USD | −11.31 مليون USD |
تم تحديث حقائق الشركة 8 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
9.00 US$
ارتفاع محتمل بنسبة 37.61%صناديق متداولة تفصح عن تعرضها لهذا السهم.
iShares Russell 2000 ETFIWM5.56 مليون0.01%78.56 مليار USD0.19%277.7 US$-1.29%
Vanguard Morningstar Total Stock Market ETFVTI5.4 مليون0.00%2.3 ترليون USD0.03%381.03 US$-0.40%
iShares Russell 2000 Growth ETFIWO2.15 مليون0.02%14.25 مليار USD0.24%355.37 US$-1.43%
Vanguard Russell 2000 ETFVTWO1.17 مليون0.01%18 مليار USD0.06%112.21 US$-1.26%
iShares Micro-Cap ETFIWC710.85 ألف0.05%1.33 مليار USD0.60%183.36 US$-1.09%
Vanguard Extended Market ETFVXF589.74 ألف0.00%95.4 مليار USD0.05%233.49 US$-1.56%
Vanguard Russell 2000 Growth ETFVTWG226.17 ألف0.01%1.7 مليار USD0.06%259.28 US$-1.46%
iShares Russell 2500 ETFSMMD117.16 ألف0.00%4.06 مليار USD0.23%85.85 US$-1.46%iShares Russell 2000 ETFIWMVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCVanguard Extended Market ETFVXFVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.
